SCHEMBL7570307

SCHEMBL7570307

CC(C)=CCOc1ccc(C(=O)/C=C/c2ccc(O)cc2)c(O)c1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.87
MEN1 O00255 4/20 0.68
LMNA P02545 4/20 0.68
MAPT P10636 4/20 0.68
KMT2A Q03164 4/20 0.68
HPGD P15428 3/20 0.68
BLM P54132 2/20 0.68
NR1I2 O75469 1/20 0.68
PGR P06401 1/20 0.68
ADRB2 P07550 1/20 0.68
ADRB1 P08588 1/20 0.68
ADORA3 P0DMS8 1/20 0.68
CNR1 P21554 1/20 0.68
TBXA2R P21731 1/20 0.68
SLC6A2 P23975 1/20 0.68
AGTR1 P30556 1/20 0.68
ADRA1A P35348 1/20 0.68
OPRD1 P41143 1/20 0.68
OPRK1 P41145 1/20 0.68
SLC6A3 Q01959 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30384812 1.00 MAOB (0.87) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL25198485 1.00 MAOB (0.87) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL30384031 0.96 MAOB (0.89) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL11394922 0.96 MAOB (0.89) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL11394919 0.96 MAOB (0.89) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL25194697 0.94 MAOB (0.81) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL30383474 0.93 MAOB (1.00) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL7636407 0.93 MAOB (1.00) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL30384372 0.92 MAOB (0.81) MAOBMEN1LMNAMAPTKMT2A
SCHEMBL7637137 0.92 MAOB (0.81) MAOBMEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES Didenko, Kirill (US) 2025-07-03 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
CN-115477611-B MRGPRX2 antagonists for the treatment of pseudoallergy 香港大学 2024-11-08 CN disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023187599-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES DIDENKO KIRILL (MX) 2023-10-05 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
WO-2023037254-A1 METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS DIDENKO KIRILL (MX) 2023-03-16 WO disclosed
US-20220401435-A1 MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS THE UNIVERSITY OF HONG KONG 2022-12-22 US disclosed
EP-3097904-B1 DEPIGMENTING AGENTS TO LIGHTEN THE SKIN AFFICHEM (FR) 2019-08-14 EP disclosed
WO-2016193220-A1 SKIN PIGMENTATION MODIFIERS TO DARKEN OR LIGHTEN THE SKIN AFFICHEM (FR) 2016-12-08 WO disclosed
EP-3097904-A1 DEPIGMENTING AGENTS TO LIGHTEN THE SKIN Affichem (FR) 2016-11-30 EP disclosed
EP-0800387-B1 CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS INDENA SPA (IT) 2002-08-28 EP disclosed
US-5808137-A Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumors INDENA S.P.A. (IT) 1998-09-15 US disclosed
EP-0800387-A1 CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS INDENA S.p.A. (IT) 1997-10-15 EP disclosed
WO-1996019209-A1 CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS INDENA S.P.A. (IT) 1996-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAOB 1004/4885MEN1 3367/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAOB 2435/4885MEN1 2457/4885LMNA 1817/4885
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES ACE2, FURIN, SARS1 MAOB 1653/4885MEN1 732/4885LMNA 1554/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAOB 2435/4885MEN1 2457/4885LMNA 1817/4885
US-20220401435-A1 MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS MRGPRX2, MRGPRX1, MRGPRX4 MAOB 2271/4885MEN1 3187/4885LMNA 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.